Global Retirement Partners LLC Boosts Position in CVS Health Corporation $CVS

Global Retirement Partners LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 54.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,109 shares of the pharmacy operator’s stock after purchasing an additional 8,102 shares during the quarter. Global Retirement Partners LLC’s holdings in CVS Health were worth $1,834,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of CVS. Wellington Management Group LLP boosted its position in CVS Health by 391.6% during the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock worth $477,273,000 after purchasing an additional 5,042,816 shares in the last quarter. Amundi boosted its position in CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after purchasing an additional 3,637,943 shares in the last quarter. Capital Research Global Investors boosted its position in CVS Health by 24.5% during the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after purchasing an additional 2,253,531 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of CVS Health by 70.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock valued at $399,125,000 after acquiring an additional 2,188,307 shares in the last quarter. Finally, Hamlin Capital Management LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at $160,844,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CVS. Morgan Stanley upped their price objective on CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Robert W. Baird upped their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Argus upped their price objective on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Finally, Mizuho upped their price objective on CVS Health from $102.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $98.68.

CVS Health Stock Performance

CVS Health stock opened at $93.24 on Friday. The firm has a market capitalization of $118.97 billion, a P/E ratio of 41.08, a PEG ratio of 0.91 and a beta of 0.60. The stock has a fifty day moving average price of $80.38 and a 200 day moving average price of $79.08. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein reiterated an Outperform rating and raised its price target on CVS to $106, saying the company is well positioned for a Medicare Advantage turnaround. Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
• Positive Sentiment: Glenview Capital said CVS has delivered about an 80% total return since May 2024, reinforcing confidence in the company’s operational turnaround and long-term investment case. Glenview Capital Issues Statement on CVS Health
• Neutral Sentiment: CVS announced a collaboration with America250 to support the nation’s 250th anniversary celebration, a brand-building move that is unlikely to have a major near-term effect on earnings. CVS Health Collaborates With America250 To Support the Nation’s 250th Anniversary Celebration
• Neutral Sentiment: Recent community and philanthropic announcements, including support for military families and senior housing, add to CVS’s public-facing story but are not likely to move the shares materially on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Negative Sentiment: Three major hospital systems, including affiliates tied to Mount Sinai, the University of Michigan, and the University of Kansas, sued CVS, alleging it siphoned about $250 million from the 340B drug program through reduced reimbursements. Hospitals sue CVS for allegedly siphoning $250M in 340B funds
• Negative Sentiment: Separate reports say hospital systems are expanding the 340B dispute, raising the risk of more litigation, settlement costs, and reputational pressure for CVS’s pharmacy-benefit operations. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
• Negative Sentiment: Director Larry Robbins disclosed several large stock sales over the past few days, including a roughly $187 million sale, which can weigh on investor sentiment even though he still owns a large stake. SEC Form 4 filing

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the sale, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. Insiders own 0.85% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.